Details up front: injection-site erythema · five · oral semaglutide.
I would like to understand the steps well enough to explain them to someone else.
I have access to a refrigerator with a logger and a freezer without one, which may be relevant.
Concretely, what should I do, and how would I know afterwards whether I did it right?
Week 5 is day 35: on a four-week ladder that is week 1 of dose step 2, and — at the seven-day half-life this class runs on — 5 half-lives in. Steady state is about five half-lives, so day 35 is where the concentration stops climbing on its own. Day 35 is exactly that point. That distinction is most of the question: at week 1 of a step, an effect that is still accumulating is indistinguishable from one that is not resolving unless you know which side of day 35 you are on. Local erythema is a site-and-technique observation before it is a drug observation. It should track where and how you injected rather than how many weeks you have been injecting, so the useful record is a rotation log rather than a week count. Dose decisions are made under supervision, and nothing here is medical advice.
The short version: usually mild, usually resolving in days, and distinguishable from infection by systemic features and by trajectory.
Immediate stinging is usually the injectate: cold solution, a preservative, or a hypotonic diluent. Room-temperature solution injected slowly removes most of it.
| Feature | Local reaction | Sterile abscess | Cellulitis |
|---|---|---|---|
| Onset | Hours to 2 days | Days | 1–4 days, progressive |
| Warmth | Absent or minimal | Mild | Marked |
| Expansion | Static or shrinking | Slow | Expanding |
| Texture | Firm, flat or raised | Fluctuant | Diffuse, indurated |
| Systemic features | None | None | Fever, malaise possible |
| Action | Observe, rotate site | Clinical review | Same-day clinical review |
On the detail: marking the edge of an area of redness with a pen and a time is the cheapest way to establish whether it is expanding, and it converts an impression into an observation.
Injection-site reactions are reported in the trial programmes for this class at low single-figure to low double-figure percentages depending on agent and formulation.
Fever or spreading redness is a clinical problem. Do not wait it out.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsStart by separating the immediate stinging on injection from a delayed reaction appearing hours later — they have different causes.
Features that point towards infection rather than reaction: expanding redness beyond a few centimetres, increasing rather than decreasing pain after forty-eight hours, warmth, fluctuance, fever or malaise.
Repeated reactions in the same anatomical area suggest inadequate rotation. Lipohypertrophy presents as a firm painless thickening and alters absorption from that site.
Cellulitis is distinguished from a local inflammatory reaction clinically by expansion, systemic features and trajectory rather than by appearance at a single time point.
Room-temperature solution, slow push, fresh needle. That removes most immediate stinging.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.